Photo by National Cancer Institute on Unsplash
 

JHM Biopharma nets another CNY 100 Mn in its Series A round only 3 months after its A1 financing

Biotechnology company JHM Biopharma announced that it had completed another CNY 100 million in Series A+ round only 3 months after its completion of Series A1 round. This round was co-led by Guangdian Capital and 3E Bioventures Capital. WinX Capital acted as an exclusive financial adviser. Only 3 months before, JHM Biopharma completed a CNY 100 million in a Series A1 round to support its biologic products for childhood genetic diseases, anti-aging, anti-virus, and new biological materials.

The funds raised in this round will be used mainly for the R&D of drug candidate pipelines, the expansion of the reserve pipeline, and the construction of a commercial manufacturing base with GMP facility requirements.

Founded in 2020, JHM Biopharma is a biotechnology company with an R&D pipeline structured around metabolism, medical aesthetics, and other large-market protein drugs. Its lead products include recombinant botulinum toxin type A and growth hormone. Moreover, it has built a nearly 8,000-square-meter GMP warehouse at Hangzhou Medical Port, which can meet the production and commercialization needs of the company's product pipeline.

Sino Biological, ACRO Biosystems, and NovoProtein are JHM Biopharma's competitors.

More By This Author:

Chinese Online Learning Platform QuantaSing Group To List On The Nasdaq
Fruit Retailer Shenzhen Pagoda Past IPO Hearing
Chinese Audio And Video SaaS Platform Baijiayun Listed On Nasdaq On 25 Dec.